Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Berges

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Current Alzheimer Research|December 24, 2013
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's diseaseRichard A Grove, Conn M Harrington, Andreas Mahler, et al.
Transfusion|May 22, 1998
Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantationJ A Pérez-Simón, M D Caballero, M Corral, et al.
The New England Journal of Medicine|July 16, 2015
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P ComponentDuncan B Richards, Louise M Cookson, Alienor C Berges, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Current Alzheimer Research|December 24, 2013
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's diseaseRichard A Grove, Conn M Harrington, Andreas Mahler, et al.
Transfusion|May 22, 1998
Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantationJ A Pérez-Simón, M D Caballero, M Corral, et al.
The New England Journal of Medicine|July 16, 2015
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P ComponentDuncan B Richards, Louise M Cookson, Alienor C Berges, et al.
Pageof 2